Click it and Unblock the Notifications
Closing Bell: Sensex Fell 270 pts, Nifty 50 Settles Below 24,800; Adani Ent, Tata Steel, Sun Pharma Top Loser
On Thursday, July 31st, the Indian stock market began with notable losses, and the Sensex and Nifty 50 saw steep drops. The decision by US President Donald Trump to impose a 25% tax on Indian imports, together with additional penalties for India's energy and defense transactions with Russia, was the main driver of this significant gap-down opening. The Nifty 50 fell below 24,650, starting at 24,642.25, while the Sensex dropped over 800 points, beginning at 80,695.50. The sell-off was widespread, with significant losses being seen in the mid- and small-cap indices. Currently, steel, pharmaceuticals, and semiconductors are exempt from reciprocal tariffs. On the global front, Asian stock markets saw mixed trading on July 31, 2025, as market players awaited the Bank of Japan's upcoming policy announcement and investors remained cautious ahead of key global economic indicators. Key earnings results from Hindustan Unilever, Sun Pharmaceutical Industries, Mahindra & Mahindra, Maruti Suzuki India, Coal India, Vedanta, and Adani Enterprises are anticipated on Thursday. As the earnings season continues and the Fed makes its interest rate decision soon, the market will continue to be closely watched.
Vedanta Limited Announced Its Q1FY26 Results
Vedanta Limited today announced its Unaudited Consolidated Results for the First Quarter ended 30 th June 2025. Records its highest ever first quarter EBITDA at Rs. 10,746cr (+5% YoY) supported by margin expansion of 81 bps to 35%. Adjusted PAT jumps 13% YoY to ₹5,000cr; PAT stands at ₹4,457cr. Net debt/ EBITDA stands at 1.3x.
Top Gainer and Losers:
HUL, Jio Finance, Eternal, Kotak Mahindra Bank, Jsw Steel, and ITC are top Nifty gainers while, Adani Entertainment, Dr Reddy, Reliance, Maruti and Coal India are top losers on the nifty at 2 PM.
Sri Lotus Developers IPO Day 2 Update: Subscribed 7.61 times So Far
The initial public offering (IPO) of Sri Lotus Developers IPO has been subscribed 7.61 times as of 1.55 PM on Thursday, the second day of bidding. The IPO opened for subscription on July 30, 2025, and will close on August 1, 2025. On its opening day, the issue was subscribed 3.86 times. Sri Lotus Developers IPO will be listed on the BSE and NSE platform. The IPO price band is set at Rs 150 per share, with a minimum lot size of 3,000 shares.
TVS Motor Q1 Results: Net Profit is 34.85%
TVS Motor has announced its earnings for the first quarter. The company posted a revenue of Rs 10,081 crore. Its net Profit is 34.85%. Its EBITDA stood at Rs 1,263 crore. The operating margin came in at 12.53%.
Nifty Rebounds, Crosses 24,900 After Early Dip
The Nifty 50 index climbed above the 24,900 level during intraday trading on Wednesday, reaching 24,938.35, up by 0.33%. The market had opened lower due to concerns over former U.S. President Donald Trump's 25% tariff announcement on India. However, it later recovered those early losses and remained stable through the session.
Gillette India Q1 Profit Rises 28% to Rs 50 Cr
Gillette India reported a 28% increase in its net profit for the first quarter, reaching Rs 50 crore. The company’s revenue also grew by 9.5%, coming in at Rs 707 crore.
Markets At 1PM, The Benchmark Indices Are Trading In Green
The Sensex is up 138.46 points or 0.17% at 81,626.75, while the Nifty 50 is up by 45.15 points or 0.18% to 24,899.95
Stock Market Live: How Trump Tariffs Would Impact Defence Sector Stocks?
Stock Market Live: "In 2024, the total India-US trade was 9 billion including billion exports from India and remaining imports from US. At around 3% of India’s GDP it is relatively small. Since, tariffs could impact the near term revenues and earnings, investors can prefer to stay away from companies with large exports to the US especially if the current market prices of the companies incorporate large growth to justify the current prices. In the Indian markets, there are a large number of companies which have practically no exposure to the US economic markets. One can focus on those companies with focus on thosw which have medium to high domestic growth driven by domestic growth vectors and where Mr. Market might not yet have discounted it in the prices. These below the radar companies is where an investor can focus his portfolio. For example, banks, power, epc/ infra, domestic business services, etc. are some of the growth vectors we hold in our portfolio or are overweight. Of course, this is not a recommendation, rather these are examples that one can find a vast array of opportunities if one follows a scientific investing framework.The scientific investing framework encourages a focus on companies with strong balance sheets, persistent competitive advantages, exposure to long-term growth vectors and which are priced at a discount to their conservatively determined intrinsic values. For the current post-tariff situation we would ideally focus on companies with low or no exposure to the US markets. In our opinion, a deal will be reached eventually and the tariffs should be lower at that point of time. So one cannot take a necessarily negative long-term view about US exporting companies until we see the final deal,” noted Vikas Gupta, CEO & Chief Investment Strategist at OmniScience Capital.
Stock Market Live:Will Trump Tariff Impact Indian Stock Markets?
Stock Market Live: "“Obviously, a ten-fold rise in tariffs will be a drag on growth, to the extent of 20-30bps. But, it would be a mistake to extrapolate the announced tariffs to eternity. We expect a trade deal in the next 6 months leading to reductions in rate of tariffs, maybe in the region of 15%. Meanwhile, do expect small cut to EPS estimates of major indices as the correlation of GDP growth and corporate profitability is highest for India vs. peers,” said Jyoti Prakash, Managing Partner. Equity and PMS at AlphaaMoney
Stock Market Live: US Stock Market Recap
Stock Market Live: On 30th July 2025, U.S. markets were mixed with S&P 500 down by -7.9 pts (-0.12%), Dow Jones was down by -171 pts (-0.38%) and Nasdaq was up by +37 pts (+0.16%). India VIX was down by ~2.78%. GIFT Nifty is trading negative at ~24,655 (-199 pts, -0.80%) indicating Indian markets will open negative. Yesterday, advance decline ratio on NSE was 1507 : 1463 and BSE was 1,992 : 2,023, which showed sluggishness in the overall markets.
Stock Market Live Updates: Nifty Falls 180 Points Below 24,700; Sensex Down 615 Points; Adani, RIL, Top Losers
Stock Market Live Updates: Nifty Falls 180 Points Below 24,700; Sensex Down 615 Points; Adani, RIL, Top Losers
Nifty Prediction Today By Anand James, Chief Market Strategist, Geojit Investments
Though the upswings did not stretch as far as 24960, rejection trades did evolve soon after breach of 24900, raising fears of a retest of 24650. Upswing attempts that are usually set off following a downside gapped opening, are expected today, and we see 24788 as an important pivot. Should 24650-600 region give away, expect 24450, but a sustained downside is less expected today. Alternatively, ability to float above 24788 will be seen as a positive sign, but it would require a breach of 24960-25050 band to play a 25330 move.
Nifty Holds Strong Amid Tariff Woes: Where Should Investors Focus?
“The 25 % tariff on India plus an unspecified penalty for energy and defence-related purchases from Russia is very bad news for Indian exports and thereby on the growth prospects of the Indian economy in the short run. Since trade negotiations with India are continuing, perhaps, the 25 % tariff may come down eventually. But certainly, there is a short-term hit to Indian exports and GDP growth. This short-term hit will reflect in the stock market, too, in the short-term. From the investor perspective it is important to understand that the 25 % tariff will come down after the negotiations which start in mid-August. The 25% tariff imposed on India is far higher than the rates reached in trade deals with other countries. This is the typical Trumpian strategy to get better deals from India in other areas and finally settle at a tariff rate around 20 % or less. Nifty is unlikely to go below the support level of 24500. Investors can buy the dip focusing on domestic consumption themes, particularly segments like leading private sector banking names, telecom, capital goods, cement, hotels and select autos which have done well in Q1,” said Dr. VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited.
Market Outlook Today By Hardik Matalia, Derivative Analyst - Research at Choice Equity Broking Private Limited
In terms of institutional activity, Foreign Institutional Investors (FIIs) extended their selling streak for the eighth consecutive session on July 30, offloading equities worth ₹850 crore. Conversely, Domestic Institutional Investors (DIIs) maintained their buying momentum for the 18th straight session, purchasing equities worth ₹1,829 crore on the same day. Given the current landscape of heightened volatility and mixed technical signals, traders are advised to adopt a cautious "sell-on-rise" strategy, particularly when operating with leverage. Booking partial profits on rallies and employing tight trailing stop-losses is essential to manage risk. Fresh long positions should only be initiated if the Nifty sustains above the 25,000 mark. While the broader market undertone remains cautiously bullish, it is crucial to monitor key technical levels and global developments closely.
Bank Nifty Outlook Today By Hardik Matalia, Derivative Analyst - Research at Choice Equity Broking Private Limited
Bank Nifty, after breaking down from a narrow consolidation range, has retested its breakdown level and is currently hovering around a crucial zone. A sustained move above 56,275 could lead to a rally toward 57,000 and 57,630. Meanwhile, support is seen at 55,500–55,150. The RSI stands at 44.14 and remains flat, indicating the absence of strong directional momentum at present. However, the broader price structure continues to reflect a bullish bias, making dips a buying opportunity for positional traders.
Nifty Outlook Today By Hardik Matalia, Derivative Analyst - Research at Choice Equity Broking Private Limited
On the technical front, the Nifty formed a bullish hammer candlestick and closed above the previous day’s high, signaling the potential for a follow-up rally. The index is currently trading above its 100-day EMA, reflecting underlying strength. A close above the 50-day EMA at 24,935 would further confirm a bullish reversal. If this level is sustained, the index could advance toward 25,200 and eventually 25,800 in the coming sessions. On the downside, support is placed in the 24,590–24,400 zone, which could act as a potential area for dip-buying.
Textiles, Pharma, Auto Components Under Pressure as Trump Tariffs Bite
“In response to President Trump’s recent imposition of a 25% tariff and penalties on Indian goods, investors will reassess their strategies with a mix of caution and optimism. Sectors like textiles, pharmaceuticals, and automotive components—key Indian exports—are likely to be most impacted and may see reduced investor interest in the short term. However, recent progress in trade negotiations suggests a constructive path forward, and we believe that the trade deal will eventually follow provided both nations show the necessary political will. Many investors expect the tariff rate to eventually settle around 15%, paving the way for renewed confidence and stronger trade ties. In the short term, market will try to shed off its complacency. We do not expect huge knee-jerk reaction but a rangebound market focused on ongoing earnings,” said Utsav Verma, Head of Research - Institutional Equities, Choice Broking.
U.S. Imposes 25% Tariff on Indian Imports; Pharma Exempt for Now
The U.S. has announced a 25% general tariff on Indian imports, effective August 1, 2025. However, drug formulations and APIs are currently excluded from this tariff, consistent with the April 2025 reciprocal tariff framework, where pharmaceuticals were explicitly exempted. “That said, we flag the ongoing Section 232 investigation into pharma imports by the U.S. as a medium-term overhang, with the potential for pharma-specific tariffs to be announced in the coming weeks or months. In the absence of clarity on the potential rate and scope of such tariffs, it remains difficult to quantify the impact on Indian pharma players at this stage. Notably, the U.S. remains heavily reliant on India for its pharmaceutical needs, with ~50% of generic drugs sourced from India. Given the critical nature of healthcare and already elevated healthcare costs in the U.S., we view the likelihood of material near-term tariffs on pharma as low,” said Maitri Sheth, Equity Research Analyst- Pharma Sector, Choice Broking. “From our initial management interactions, we understand that: Larger players with manufacturing facilities in the U.S. are likely to remain broadly insulated and others anticipate a limited impact, with plans to pass on incremental costs to customers where feasible. In our view, while the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the U.S. healthcare system provide a strong case against aggressive tariff action on the sector,” Maitri Sheth further added.
Sign in with Google